Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens

Bank of America

Citigroup

Goldman Sachs

JPMorgan Chase & Co

Schlumberger

United Continental Hlds

UnitedHealth Group

Wells Fargo

A new earnings reporting season kicks off this week, with the big banks and a few other companies leading the way.

Citigroup, Goldman Sachs, Johnson & Johnson, Walgreens and More Major Earnings This Week

Becton, Dickinson and Co.

Essex Property Trust

General Dynamics

Kimberly-Clark

5 Resilient Low-Risk Dividend Aristocrats For A Volatile Fall

Novavax

These COVID-19 vaccine leaders offer very different risk-reward propositions.

Better Coronavirus Stock: Johnson & Johnson vs. Novavax

J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.

Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings

Cardinal Health

CVS Health

Diageo

Orrstown Financial

Vanguard High Dividend Yield ETF

Essential Utilities

In total, my dividend stock purchases of VYM totaled $1,140.63, acquiring 14 total shares.

Dividend Stock Purchase: Lanny's September 2020 Summary

AstraZeneca

Invesco DWA SmallCap Momentum ETF

Inovio Pharmaceuticals

iShares Russell 2000 Growth ETF

iShares Morningstar Small-Cap Growth ETF

Merck

Moderna

Pfizer

Vanguard Small-Cap Growth

Vanguard Russell 2000 Growth 

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

Here's Why Small-Cap ETFs Are Hitting New Highs

Our indicative theme of Coronavirus Vaccine stocks – which includes a diverse set of U.S. based pharma and biotech stocks that are working on Covid-19 vaccines – is up by about 730% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 4% over the same.

Moderna, Pfizer, Johnson & Johnson: How Are Covid Vaccine Stocks Doing?

Coca-Cola

Walmart

Blue-chip stocks should look especially attractive to investors now that uncertainty reigns. Read on to learn which are strongest.

5 Blue-chip Stocks to Buy on a Discount to Fortify Portfolios

Huntington Ingalls Industries

Kellogg

Olin

Robert Half Int.

Raytheon Technologies

Because of the unprecedented Covid-19 crisis, many discounted securities appear to be value stocks. Here are seven names that truly deserve that designation.

7 High-Growth Value Stocks for a Post-Pandemic Future

BioNTech SE

Pharmaceutical companies developing COVID-19 vaccines should wait two months after late-stage studies conclude to submit an application for an emergency use authorization to the Food and Drug Administration, the regulator said Tuesday.

FDA to require 2-month follow-up period for COVID-19 vaccines before authorization

That is likely only the tip of the iceberg, however.

Report: Johnson & Johnson Paying Over $100 Million to Settle Baby Powder Lawsuits

Last year, the company recalled 33,000 bottles of baby powder after trace amounts of asbestos were found.

Johnson & Johnson To Pay $100 Million In Baby Powder Settlement

Johnson & Johnson will pay more than $100 million to settle over 1,000 lawsuits that allege the company’s Baby Powder caused cancer, Bloomberg News reported on Monday, citing people with knowledge of the pacts. J&J faces more than 19,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with.

Johnson & Johnson settles baby powder lawsuits for $100M

Johnson & Johnson will pay more than $100 million to settle over 1,000 lawsuits that allege the company's Baby Powder caused cancer, Bloomberg news reported on Monday https://www.bloomberg.com/news/articles/2020-10-05/j-j-to-pay-more-than-100-million-to-end-over-1-000-talc-suits?utm_campaign=socialflow-organic&utm_medium=social&utm_source=twitter&cmpid=socialflow-twitter-business&utm_content=business&sref=WJKVI5nK, citing people with knowledge of the pacts.

Johnson & Johnson to pay more than $100 million to settle over 1,000 talc lawsuits: Bloomberg

Alexion Pharma

These drugmakers have cornered the markets they need in order to flourish in the long term.

2 Timeless Pharma Stocks to Buy After the Next Market Crash

Sometimes it pays to know about the nuts and bolts of the clinical trial process.

Everything Investors Need to Know About Investigational New Drug Submissions

Bristol-Myers

Cerner

Colgate-Palmolive

Costco

Dollar General

General Mills

Hormel Foods

Republic Services

The stock market suffered a turbulent September, and a number of factors are pointing toward an equally bumpy rest of the year. That likely will have investors looking for a smoother market ride than what the major indices have to offer – and one such way to do that is to buy low-volatility stocks to manage risk.

12 Low-Volatility Stocks to Stabilize Your Portfolio

News for Johnson & Johnson Stock (JNJ)